The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
This article was originally published in Pharmaceutical Approvals Monthly
The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.
You may also be interested in...
For more than 15 years, the Pink Sheet's Drug Review Profile series has looked closely at FDA approval documents, providing a long view of the pitfalls and pitches presented in the NEJM series on interpreting clinical trial results.
The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.